Last updated: August 22, 2026
GoodSense Dual Action Complete is positioned as a private-label combination analgesic containing acetaminophen and ibuprofen, generally corresponding to the Advil Dual Action product concept. Its commercial opportunity depends on low-cost immediate-release manufacturing, acceptable tablet size, dose uniformity, packaging differentiation, and careful management of acetaminophen and NSAID regulatory risks. The strongest excipient strategy is a robust, conventional caplet platform that supports rapid dissolution, high-speed compression, low friability, and broad retail distribution.
What is GoodSense Dual Action Complete?
GoodSense Dual Action Complete is marketed as a combination pain reliever using two different mechanisms:
| Component |
Typical labeled strength per unit |
Function |
| Acetaminophen |
250 mg |
Analgesic and antipyretic |
| Ibuprofen |
125 mg |
NSAID analgesic, antipyretic, and anti-inflammatory |
The product is generally positioned as an immediate-release oral tablet or caplet for temporary relief of minor aches and pains. Its commercial reference product is Advil Dual Action, marketed by Haleon.
The combination allows a private-label product to compete against single-ingredient acetaminophen, ibuprofen, aspirin, and branded combination analgesics. The principal commercial advantage is consumer convenience: one dosage unit provides both active ingredients.
What excipient platform is appropriate for the product?
A direct-compression or dry-granulation formulation is the most commercially attractive platform. Both active ingredients have high drug loading, so the formulation must control blend uniformity, tablet weight, hardness, friability, dissolution, and caplet dimensions.
Recommended functional excipient architecture
| Formulation function |
Candidate excipient classes |
Commercial rationale |
| Diluent |
Microcrystalline cellulose, dibasic calcium phosphate, pregelatinized starch |
Supports compactability and tablet size control |
| Binder |
Povidone, copovidone, pregelatinized starch |
Improves mechanical strength |
| Disintegrant |
Croscarmellose sodium, crospovidone, sodium starch glycolate |
Promotes rapid breakup after ingestion |
| Lubricant |
Magnesium stearate, sodium stearyl fumarate |
Supports ejection and high-speed tableting |
| Glidant |
Colloidal silicon dioxide |
Improves powder flow and feed consistency |
| Film coating |
Hypromellose, polyethylene glycol, mineral pigments |
Improves swallowability, appearance, and product identification |
| Taste and odor control |
Film coating, colorants, flavor-masking technologies |
Reduces perception of ibuprofen or acetaminophen taste |
The formulation should avoid unnecessary excipient complexity. A short excipient list lowers raw-material costs, simplifies supplier qualification, reduces compatibility variables, and makes private-label scale-up easier.
How should the formulation manage acetaminophen and ibuprofen?
The two active ingredients create different formulation and regulatory concerns.
Acetaminophen is present at a relatively high mass fraction and can drive tablet size. Ibuprofen has poor aqueous solubility and can create dissolution sensitivity, lubrication problems, and powder-flow issues. Excessive magnesium stearate or extended lubrication can slow dissolution, particularly for poorly soluble ibuprofen.
A preferred development sequence is:
- Establish a direct-compression blend using a high-functionality filler.
- Screen disintegrant type and concentration against ibuprofen dissolution.
- Optimize lubricant level and lubrication time.
- Evaluate tablet hardness against disintegration and dissolution.
- Add a thin film coat only after the core meets performance specifications.
- Confirm stability under accelerated and long-term conditions.
The main critical quality attributes should include assay of both actives, content uniformity, dissolution of each active, tablet weight, hardness, friability, disintegration, moisture, and degradation products.
Which excipients offer the strongest commercial value?
Microcrystalline cellulose
Microcrystalline cellulose is a leading candidate for direct compression because it improves compactability at relatively low concentrations. It can reduce the need for wet granulation and support high-speed manufacture. Its limitations include sensitivity to moisture and potential variability in tablet strength across compression speeds.
Dibasic calcium phosphate
Dibasic calcium phosphate can reduce tablet volume and improve flow. It is useful where a smaller caplet is commercially important. Its low deformability can increase the need for a complementary binder or plastic excipient. The formulation must be screened for dissolution impact and abrasive behavior.
Crospovidone
Crospovidone can support rapid disintegration without substantial swelling. It is attractive for an immediate-release product where fast tablet breakup is a key performance objective. Cost is generally higher than some starch-based alternatives.
Croscarmellose sodium
Croscarmellose sodium is a cost-effective disintegrant with broad use in oral solid dosage forms. Excessive concentrations can affect compactability and may create processing variability. It should be screened with the selected filler and lubricant system.
Sodium stearyl fumarate
Sodium stearyl fumarate can be evaluated where magnesium stearate produces unacceptable dissolution delay. It may offer a useful alternative for a high-throughput tablet line, although supplier cost and qualification requirements can be higher.
What formulation patents may affect GoodSense Dual Action Complete?
The active ingredients are established small molecules with extensive prior art. The principal intellectual-property exposure is therefore more likely to arise from:
- Fixed-dose acetaminophen/ibuprofen combinations
- Specific dose ratios
- Immediate-release or multilayer tablet designs
- Modified-release delivery systems
- Coated particles or taste-masked particles
- Gastrointestinal tolerability technologies
- Manufacturing processes
- Packaging and dosing systems
- Method-of-use claims covering simultaneous or sequential administration
A conventional immediate-release tablet using ordinary pharmaceutical excipients generally has a narrower patent exposure profile than a modified-release, gastroprotective, liquid, effervescent, or multiparticulate product. A freedom-to-operate review should focus on active-ingredient combinations, dose ratios, release profiles, and formulation-specific claims rather than the mere use of common excipients.
Patent status should be checked by jurisdiction through the USPTO, WIPO, FDA Orange Book, and applicable national registers. Orange Book coverage is relevant only if the reference product has listed patents and the competing product is submitted through an ANDA pathway that relies on the reference product. FDA’s Orange Book does not provide a complete record of every formulation or manufacturing patent relevant to a combination analgesic. [1, 2]
What regulatory pathway applies to the product?
A U.S. product containing acetaminophen and ibuprofen may be regulated through an approved application or an applicable OTC framework, depending on the product’s formulation, labeling, dosage, and legal basis. The product’s actual regulatory status should be determined from its FDA listing, National Drug Code records, labeling, and application history.
Relevant regulatory issues include:
- Acetaminophen liver-toxicity warnings
- Ibuprofen gastrointestinal bleeding, cardiovascular, renal, and pregnancy warnings
- Maximum daily dose labeling
- Duplicate-ingredient warnings
- Pediatric use and age restrictions
- Label prominence and readability
- Drug Facts compliance
- Stability and dissolution requirements
- Manufacturing under current good manufacturing practice
FDA has repeatedly emphasized the risk of unintentional acetaminophen overdose from multiple products. A dual-action product therefore requires clear front-panel and Drug Facts labeling to distinguish it from single-ingredient acetaminophen and ibuprofen products. [3]
What commercial opportunities exist for the excipient strategy?
Lower-cost store-brand analgesics
The primary opportunity is a lower-price alternative to Advil Dual Action. Private-label retailers can use the same active-ingredient concept with a simpler excipient system, lower marketing expenditure, and larger-count packaging.
The commercial model is strongest where the manufacturer can achieve:
- Direct compression
- High line speed
- Low tablet rejection
- Stable supply of acetaminophen and ibuprofen
- Standardized coating materials
- Retailer-specific packaging
- Multi-count packaging efficiencies
Small-caplet and easy-swallow formats
A smaller caplet can create differentiation in a crowded OTC market. This may require higher-density fillers, optimized compaction, or a bilayer design. A smaller unit can improve consumer acceptance but may increase manufacturing complexity and patent exposure.
Gelcap and liquid-filled formats
Softgel or liquid-filled formats may offer faster perceived onset and easier swallowing. They require different excipient systems, including liquid vehicles, gelatin or non-gelatin shells, plasticizers, and compatibility controls. Ibuprofen solubility and acetaminophen loading can limit the feasibility of a fully liquid formulation.
Gastrointestinal-positioned products
A formulation marketed around tolerability could attract consumers who are sensitive to NSAID stomach effects. Commercial claims must remain within permitted labeling and cannot imply that excipients eliminate established ibuprofen risks. A gastroprotective combination would create a materially different regulatory and patent profile.
E-commerce and subscription packaging
The product is suitable for multipacks, household-size counts, club-store packaging, and subscription sales. Packaging rather than formulation may provide the fastest route to commercial differentiation. Unit-dose blister packs could improve portability and reduce accidental exposure, although they increase packaging cost.
How does GoodSense compare with competing analgesics?
| Product type |
Main advantage |
Main limitation |
Excipient opportunity |
| Acetaminophen alone |
Broad consumer familiarity |
No anti-inflammatory activity |
Smaller, low-cost tablet |
| Ibuprofen alone |
Anti-inflammatory activity |
NSAID warnings and tolerability concerns |
Rapid-disintegration caplet |
| Acetaminophen/ibuprofen combination |
Dual mechanism and convenience |
More complex warning profile |
Compact immediate-release dosage form |
| Aspirin combinations |
Established analgesic use |
Bleeding and tolerability concerns |
Effervescent or coated formats |
| Branded dual-action products |
Consumer recognition |
Higher price |
Private-label price competition |
The combination product has the clearest value proposition against consumers who would otherwise take separate acetaminophen and ibuprofen products. Its principal disadvantage is a more complex safety message and a larger active-ingredient load per dose.
What manufacturing and supply-chain barriers exist?
Manufacturing risk is moderate rather than technologically extreme. The main barriers are operational:
- Achieving uniform distribution of two active ingredients
- Controlling ibuprofen dissolution
- Preventing over-lubrication
- Managing acetaminophen degradation
- Maintaining caplet dimensions
- Controlling dust and cross-contamination
- Qualifying multiple active-ingredient suppliers
- Meeting retailer cost targets
- Preserving dissolution after film coating
- Maintaining packaging-line throughput
A dual-source strategy for acetaminophen, ibuprofen, coating polymers, and disintegrants can reduce supply interruptions. Supplier changes require comparability assessment because particle size, morphology, density, and moisture can change blend behavior even when the material meets compendial specifications.
What is the patent strength of a conventional dual-action tablet?
A conventional immediate-release product using acetaminophen, ibuprofen, and standard excipients generally has moderate formulation differentiation and limited defensibility. Common excipients are difficult to protect broadly because they are widely used and supported by extensive prior art.
Patent strength improves when the product includes:
- A novel release profile
- A specific particle-engineering approach
- A validated reduction in gastrointestinal exposure
- A stable high-load composition
- A multilayer or multiparticulate structure
- A distinctive manufacturing process
- A clinically supported dosing regimen
For GoodSense, the commercial moat is more likely to come from retailer distribution, procurement scale, brand placement, price, and manufacturing reliability than from broad composition-of-matter protection.
What generic launch risks exist?
The most plausible launch risks are regulatory and commercial:
- A competing private-label product may reach market with materially lower cost.
- A branded manufacturer may expand pack sizes or discount aggressively.
- A formulation change may cause dissolution or stability failure.
- Labeling may create consumer confusion with single-ingredient products.
- Retailers may prioritize their own private-label supply.
- An unlisted formulation or manufacturing patent may create litigation exposure.
- Supply disruption may affect one of the two active ingredients.
- Adverse-event publicity involving acetaminophen or ibuprofen may reduce category demand.
Paragraph IV litigation is relevant only where a competitor relies on an approved reference product and certifies against listed patents. A conventional OTC private-label product may instead rely on a monograph or another regulatory pathway, depending on its legal status. The absence of an Orange Book-listed patent does not establish complete freedom to operate. [1, 2]
Key Takeaways
- GoodSense Dual Action Complete is commercially aligned with an acetaminophen/ibuprofen immediate-release analgesic.
- Direct compression is the leading cost-control strategy.
- Microcrystalline cellulose, dibasic calcium phosphate, crospovidone, croscarmellose sodium, and carefully controlled lubrication are the principal excipient options.
- Ibuprofen dissolution and lubrication control are the most important formulation-development issues.
- The strongest opportunities are private-label pricing, compact caplets, multipacks, e-commerce packaging, and easy-swallow formats.
- Patent defensibility is likely to be stronger for novel release, particle, manufacturing, or tolerability technologies than for a conventional tablet.
- Regulatory execution must address acetaminophen overdose risk and ibuprofen NSAID warnings with prominent, compliant labeling.
- Commercial advantage is more likely to derive from procurement, retailer access, manufacturing scale, and packaging than from common-excipient patents.
FAQs
Can GoodSense Dual Action Complete use the same excipients as Advil Dual Action?
It can use comparable excipient classes, but it does not need to duplicate the reference product’s exact formulation. The selected excipients must support equivalent quality attributes, regulatory compliance, stability, and dissolution.
Is a fixed-dose acetaminophen and ibuprofen product easier to patent?
No. The active ingredients and their analgesic use are heavily established. Patent strength generally depends on a specific formulation, release profile, manufacturing process, or clinically differentiated use.
Which excipient is most important for rapid onset?
The disintegrant and lubricant system usually have the greatest direct impact on tablet breakup and dissolution. Ibuprofen particle properties and tablet hardness also materially affect performance.
Can the product be reformulated as an orally disintegrating tablet?
Yes, but the high combined active load makes tablet mass, taste, mechanical strength, and mouthfeel difficult to manage. An orally disintegrating format would require a distinct formulation and regulatory evaluation.
Does an OTC combination analgesic need an Orange Book patent listing?
Not necessarily. Orange Book listing depends on the product’s regulatory pathway and approved application status. OTC monograph products and products relying on other legal pathways may not have the same patent-listing profile as ANDA products referencing an approved NDA.
References
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Patent and exclusivity information.
- U.S. Food and Drug Administration. (2023). Acetaminophen and drug safety communication.
- U.S. Food and Drug Administration. (2024). Inactive ingredient database.
- United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary.
